Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma

Cancer

Volumn 118, Issue 24, 2012, Pages 6188-6198

  Lin, Moubin ^a   Eng, Cathy ^a   Hawk, Ernest T ^a   Huang, Maosheng ^a   Lin, Jie ^a   Gu, Jian ^a   Ellis, Lee M ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

colorectal cancer; recurrence; single nucleotide polymorphism; ultraconserved elements

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COLORECTAL CARCINOMA; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; UNTRACONSERVED ELEMENT;

ADENOCARCINOMA; ANIMALS; COLORECTAL NEOPLASMS; CONSERVED SEQUENCE; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RATS; SURVIVAL RATE;

EID: 84870671896     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27653     Document Type: Article

References (33)

1. Staib L, Link KH, Blatz A, Beger HG,. Surgery of colorectal cancer: surgical morbidity and 5- and ten-year results in 2400 patients- monoinstitutional experience. World J Surg. 2002; 26: 59-66.
2. Pohl A, Lurje G, Manegold PC, Lenz HJ,. Pharmacogenomics and -genetics in colorectal cancer. Adv Drug Deliv Rev. 2009; 61: 375-380.
3. Sengupta N, Gill KA, MacFie TS, et al. Management of colorectal cancer: a role for genetics in prevention and treatment? Pathol Res Pract. 2008; 204: 469-477.
4. Risch N,. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev. 2001; 10: 733-741.
5. Baira E, Greshock J, Coukos G, Zhang L,. Ultraconserved elements: genomics, function and disease. RNA Biol. 2008; 5: 132-134.
6. Calin GA, Liu CG, Ferracin M, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007; 12: 215-229.
7. Pennacchio LA, Ahituv N, Moses AM, et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature. 2006; 444: 499-502.
8. Ni JZ, Grate L, Donohue JP, et al. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 2007; 21: 708-718.
9. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006; 125: 315-326.
10. Feng J, Bi C, Clark BS, Mady R, Shah P, Kohtz JD,. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes Dev. 2006; 20: 1470-1484.
11. Drake JA, Bird C, Nemesh J, et al. Conserved noncoding sequences are selectively constrained and not mutation cold spots. Nat Genet. 2006; 38: 223-227.
12. Katzman S, Kern AD, Bejerano G, et al. Human genome ultraconserved elements are ultraselected. Science. 2007; 317: 915.
13. Yang R, Frank B, Hemminki K, et al. SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis. 2008; 29: 351-355.
14. Bejerano G, Pheasant M, Makunin I, et al. Ultraconserved elements in the human genome. Science. 2004; 304: 1321-1325.
15. Taccioli C, Fabbri E, Visone R, et al. UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. Nucleic Acids Res. 2009; 37 (database issue): D41-D48.
16. Nobrega MA, Ovcharenko I, Afzal V, Rubin EM,. Scanning human gene deserts for long-range enhancers [serial online]. Science. 2003; 302: 413.
17. Licastro D, Gennarino VA, Petrera F, Sanges R, Banfi S, Stupka E,. Promiscuity of enhancer, coding and non-coding transcription functions in ultraconserved elements [serial online]. BMC Genomics. 2010; 11: 151.
18. Visel A, Prabhakar S, Akiyama JA, et al. Ultraconservation identifies a small subset of extremely constrained developmental enhancers. Nat Genet. 2008; 40: 158-160.
19. Cole AR, Lewis LP, Walden H,. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat Struct Mol Biol. 2010; 17: 294-298.
20. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003; 35: 165-170.
21. Wang W,. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007; 8: 735-748.
22. Zhang J, Zhao D, Park HK, et al. FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest. 2010; 120: 1524-1534.
23. Lyakhovich A, Surralles J,. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett. 2006; 232: 99-106.
24. Luyimbazi D, Akcakanat A, McAuliffe PF, et al. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010; 9: 2770-2784.
25. Woo KT, Lau YK, Wong KS, Zhao Y, Chan CM,. Parallel genotyping of 10,204 single nucleotide polymorphisms to screen for susceptible genes for IgA nephropathy. Ann Acad Med Singapore. 2009; 38: 894-899.
26. Liu F, Arias-Vasquez A, Sleegers K, et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007; 81: 17-31.
27. Kalady MF, Dejulius K, Church JM, Lavery IC, Fazio VW, Ishwaran H,. Gene signature is associated with early stage rectal cancer recurrence. J Am Coll Surg. 2010; 211: 187-195.
28. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 1797-1806.
29. Liao D,. Emerging roles of the EBF family of transcription factors in tumor suppression. Mol Cancer Res. 2009; 7: 1893-1901.
30. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446: 758-764.
31. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
32. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806.
33. Patino-Garcia A, Zalacain M, Folio C, et al. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2009; 15: 5082-5091.